Download PDF
Thromb Haemost 2017; 117(05): 823-825
DOI: 10.1160/TH17-03-0180
Invited Editorial Focus
Schattauer GmbH

Mortality and cancer risk on long-term antiplatelet treatment: What is known and what we still don’t know

Dirk Sibbing
1   Medizinische Klinik und Poliklinik I, Klinikum der Universität, Ludwig Maximilians-Universität München, Germany
2   DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany
,
Dániel Aradi
3   Department of Cardiology, Heart Center Balatonfüred, Semmelweis University, Budapest, Hungary
4   Heart and Vascular Center, Semmelweis University, Budapest, Hungary
› Author Affiliations
Further Information

Publication History

Received: 14 March 2017

Accepted: 14 March 2017

Publication Date:
13 November 2017 (online)

Also available at
    Permissions and Reprints

 

Editorial Focus on: Serebruany et al. Thromb Haemost 2017; 117: 934-939.

 

  • References

  • 1 Mauri L, Kereiakes DJ, Yeh RW. et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014; 371: 2155-2166.
    CrossrefPubMedSearch in Google Scholar
  • 2 Collet JP, Silvain J, Barthelemy O. et al. Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial. Lancet 2014; 384: 1577-1585.
    CrossrefPubMedSearch in Google Scholar
  • 3 Navarese EP, Andreotti F, Schulze V. et al. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. Br Med J 2015; 350: h1618.
    CrossrefPubMedSearch in Google Scholar
  • 4 Palmerini T, Benedetto U, Bacchi-Reggiani L. et al. Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials. Lancet 2015; 385: 2371-2382.
    CrossrefPubMedSearch in Google Scholar
  • 5 Elmariah S, Mauri L, Doros G. et al. Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis. Lancet 2015; 385: 792-798.
    CrossrefPubMedSearch in Google Scholar
  • 6 Lagerqvist B, James SK, Stenestrand U. et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007; 356: 1009-1019.
    CrossrefPubMedSearch in Google Scholar
  • 7 Shuchman M. Trading restenosis for thrombosis? New questions about drug-eluting stents. N Engl J Med 2006; 355: 1949-1952.
    CrossrefPubMedSearch in Google Scholar
  • 8 Mauri L, Elmariah S, Yeh RW. et al. Causes of late mortality with dual antiplatelet therapy after coronary stents. Eur Heart J 2016; 37: 378-385.
    PubMedSearch in Google Scholar
  • 9 Serebruany VL, Kim MH, Cabrera-Fuentes HA. et al. Mortality and cancer after 12 versus 30 months dual antiplatelet therapy. The Korean Outcomes Registry Evaluating Antithrombotics (KOREA). Thromb Haemost 2017; 117: 934-939.
    Thieme ConnectPubMedSearch in Google Scholar
  • 10 Serebruany VL, Cherepanov V, Cabrera-Fuentes HA. et al. Solid cancers after antiplatelet therapy: Confirmations, controversies, and challenges. Thromb Haemost 2015; 114: 1104-1112.
    Thieme ConnectPubMedSearch in Google Scholar
  • 11 Floyd JS, Serebruany VL. Prasugrel as a potential cancer promoter: review of the unpublished data. Arch Intern Med 2010; 170: 1078-1080.
    CrossrefPubMedSearch in Google Scholar
  • 12 Leader A, Zelikson-Saporta R, Pereg D. et al. The Effect of Combined Aspirin and Clopidogrel Treatment on Cancer Incidence. Am J Med. 2017 Epub ahead of print.
    PubMedSearch in Google Scholar
  • 13 Kotronias RA, Kwok CS, Wong CW. et al. Cancer Event Rate and Mortality with Thienopyridines: A Systematic Review and Meta-Analysis. Drug Saf 2017; 40: 229-240.
    CrossrefPubMedSearch in Google Scholar
  • 14 Roe MT, Cyr DD, Eckart D. et al. Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome. Eur Heart J 2016; 37: 412-422.
    PubMedSearch in Google Scholar
  • 15 Bonaca MP, Bhatt DL, Cohen M. et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015; 372: 1791-1800.
    CrossrefPubMedSearch in Google Scholar
  • 16 Dulai PS, Singh S, Marquez E. et al. Chemoprevention of colorectal cancer in individuals with previous colorectal neoplasia: systematic review and network meta-analysis. Br Med J 2016; 355: i6188.
    PubMedSearch in Google Scholar
  • 17 Sibbing D, Massberg S. Dual antiplatelet treatment after stenting: is longer better?. Lancet 2014; 384: 1553-1555.
    CrossrefPubMedSearch in Google Scholar
  • 18 Vries MJ, van der Meijden PE, Henskens YM. et al. Assessment of bleeding risk in patients with coronary artery disease on dual antiplatelet therapy. A systematic review. Thromb Haemost 2016; 115: 7-24.
    Thieme ConnectPubMedSearch in Google Scholar
  • 19 Yeh RW, Secemsky EA, Kereiakes DJ. et al. Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. J Am Med Assoc 2016; 315: 1735-1749.
    CrossrefPubMedSearch in Google Scholar
  • 20 Lip GY, Windecker S, Huber K. et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J 2014; 35: 3155-3179.
    CrossrefPubMedSearch in Google Scholar